CEP295NL: A Potential Drug Target and Biomarker (G100653515)

Target Name: CEP295NL

NCBI ID: G100653515

CEP295NL: A Potential Drug Target and Biomarker

The search for new drug targets and biomarkers has become a major focus in the pharmaceutical industry in recent years. These targets are essential for the development of new treatments for various diseases, including cancer. One potential drug target that is being explored is CEP295NL, a protein that is expressed in various tissues and cell types in the body.

CEP295NL is a cell surface glycoprotein that is characterized by its high expression in the liver, pancreas, and other tissues. It is composed of four chains, including a N-terminal alpha chain, a middle chain, a T-terminal beta chain, and a C-terminal gamma chain. The CEP295NL protein is involved in various physiological processes in the body, including cell signaling, inflammation, and metabolism.

One of the key functions of CEP295NL is its role in the immune system. CEP295NL has been shown to play a critical role in the regulation of immune cell function, specifically in the T cell lineage. CEP295NL has been shown to interact with the protein PD-L1, which is a negative regulator of T cell activation. This interaction between CEP295NL and PD-L1 has been shown to promote the development of T cell malignancy.

In addition to its role in the immune system, CEP295NL has also been shown to be involved in various signaling pathways in the body. For example, CEP295NL has been shown to be involved in the PI3K/Akt signaling pathway, which is a critical pathway involved in cell signaling and metabolism.

The potential drug target for CEP295NL is based on its involvement in the immune system and its potential to promote the development of T cell malignancy. Drugs that target CEP295NL have the potential to treat various diseases, including T cell malignancies, autoimmune diseases, and metabolic disorders.

In conclusion, CEP295NL is a protein that is being explored as a potential drug target and biomarker. Its role in the immune system and its potential to promote the development of T cell malignancy make it an attractive target for new therapies. Further research is needed to fully understand the mechanisms of CEP295NL and its potential as a drug target.

Protein Name: CEP295 N-terminal Like

More Common Targets